Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Ahead of print articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 25, Number 8—August 2019

Cross-Protection of Dengue Virus Infection against Congenital Zika Syndrome, Northeastern Brazil

Celia Pedroso1, Carlo Fischer1, Marie Feldmann1, Manoel Sarno, Estela Luz, Andrés Moreira-Soto, Renata Cabral, Eduardo Martins Netto, Carlos Brites, Beate M. Kümmerer, and Jan Felix DrexlerComments to Author 
Author affiliations: Universidade Federal de Bahia, Salvador, Brazil (C. Pedroso, M. Sarno, E. Luz, R. Cabral, E. Martins Netto, C. Brites); Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin Humbolt-Universität zu Berlin and Berlin Institute of Health, Institute of Virology, Berlin, Germany (C. Fischer, A. Moreira-Soto, J.F. Drexler); University of Bonn Medical Centre, Bonn, Germany (M. Feldmann, B.M. Kümmerer); German Centre for Infection Research (B.M. Kümmerer, J.F. Drexler)

Suggested citation for this article


The Zika virus outbreak in Latin America resulted in congenital malformations, called congenital Zika syndrome (CZS). For unknown reasons, CZS incidence was highest in northeastern Brazil; one potential explanation is that dengue virus (DENV)–mediated immune enhancement may promote CZS development. In contrast, our analyses of historical DENV genomic data refuted the hypothesis that unique genome signatures for northeastern Brazil explain the uneven dispersion of CZS cases. To confirm our findings, we performed serotype-specific DENV neutralization tests in a case–control framework in northeastern Brazil among 29 Zika virus–seropositive mothers of neonates with CZS and 108 Zika virus–seropositive control mothers. Neutralization titers did not differ significantly between groups. In contrast, DENV seroprevalence and median number of neutralized serotypes were significantly lower among the mothers of neonates with CZS. Supported by model analyses, our results suggest that multitypic DENV infection may protect from, rather than enhance, development of CZS.

The 2015–2016 Zika epidemic in Brazil was associated with congenital malformations summarized as congenital Zika syndrome (CZS) (16). As a consequence, abortion requests and pregnancy delays increased dramatically in Brazil and all of Latin America (7,8). For unknown reasons, CZS incidence was highest in northeastern Brazil (1,4,9,10). In Asia and Africa, where Zika virus circulated for much longer than it did in the Americas, Zika virus infections have not been consistently linked to CZS development; only sporadic cases have been reported (11). Thus, CZS development might be affected by >1 cofactor (9,12). The hypothetical list of cofactors affecting CZS development includes maternal vaccination history (12), exposure to larvicides (5), or socioeconomic factors (1,13).

Similar to the ubiquitous dengue virus (DENV), which occurs as 4 distinct serotypes, Zika virus is a flavivirus (14). Secondary DENV infections can be more severe than primary infections because of antibody-dependent enhancement (i.e., heterotypic subneutralizing antibodies enhancing virus entry into poorly susceptible cells) (15,16). Zika virus infection can also be enhanced by DENV antibodies in vitro (17,18) and in mice (19). Thus, DENV-mediated antibody-dependent enhancement may be a major cofactor of CZS development in humans (1921). However, antibody-dependent enhancement was not observed in experimentally Zika virus–infected nonhuman primates (22) and during pivotal epidemiologic studies from Brazil that assessed neither individual DENV serotypes nor microcephaly cases (5,9,23). In addition, DENV is ubiquitous in all regions of Brazil (20). Therefore, to explain the accumulation of CZS cases in northeastern Brazil, a hypothetical DENV-mediated effect enhancing CZS development would require region-specific differences in past DENV exposure. To investigate the role that preexisting DENV immunity has in CZS development, we conducted serologic testing in a nested case–control framework and analyzed historical DENV genomic data from Brazil.

Materials and Methods

Study Population

We compared 29 mothers of children born with CZS (cases) and 108 mothers of children born without CZS (controls) from Salvador, northeastern Brazil. All mothers had evidence of past Zika virus exposure, determined by use of ELISAs and plaque-reduction neutralization tests (PRNTs) as described previously (13). Samples were collected consecutively at the time of delivery from May 2015 through December 2016 at the University of Bahia Climério de Oliveira maternity ward (Appendix Figure). The study was approved by the Institutional Research Ethics Board under protocol no. 1.408.49, and all women delivering during that period accepted participation in the protocol. Age distributions of cases and controls did not differ significantly (median age 26 years for cases, interquartile range 22.0–33.5; median age 29 years for controls, interquartile range 23.3–34.0; p = 0.26 by t-test).

Diagnosis of CZS

CZS was diagnosed by attending gynecologists. Lead symptoms of CZS, as defined by Moore et al. (24), included microcephaly and other neurologic birth defects (e.g., intracranial calcifications, ventriculomegaly, dysgenesis of the corpus callosum, Dandy-Walker–like malformations, hydranencephaly, porencephaly, hydrocephalus, severe intracranial calcifications, and decreased brain tissue) (13). Microcephaly was identified when the measurement of the cephalic circumference was 2 SDs below that of neonates of the corresponding gestational age, according to intergrowth charts from the World Health Organization in addition to clinical and imaging data.


For the serotype-specific PRNT for DENV, we used 3 μL of heat-inactivated serum (56°C, 30 min) diluted by using Dulbecco modified Eagle medium, supplemented with 1% fetal calf serum at 1:50, 1:150, 1:450, 1:1,350, 1:4,050, and 1:12,150. We split serum dilutions into 4 equal aliquots and incubated them separately in 96-well plates with 60 PFUs of DENV serotypes 1–4 (Appendix Table 1) for 60 min at 37°C. Next, we incubated the virus/serum mixtures for 90 min at 37°C in 5% CO2 on Vero cells grown in 24-well plates, followed by a methylcellulose/minimum essential medium overlay (2% fetal calf serum, 1.2% final methylcellulose concentration). After incubation for 4 days (DENV-1, -3, and -4) or 5 days (DENV-2), we performed formaldehyde fixation, crystal violet staining, and plaque counting. We calculated neutralizing antibody titers by using the built-in variable slope model in GraphPad Prism 6 (GraphPad Software, LLC, Any titer >1:10 that reduced DENV PFU by >90% compared with control titers was considered positive. PRNT is the standard for flavivirus serology. DENV vaccine studies commonly rely on 50% plaque reduction to determine DENV serotype-specific antibody responses (25). To minimize the effect of potential cross-reactivity between DENV serotypes on our results, we selected a less sensitive but highly specific 90% PRNT (PRNT90).

Phylogenetic Analyses

For phylogenetic analyses, we retrieved all DENV sequences available from GenBank as of June 15, 2018, that contained information on year and place of isolation. We constructed neighbor-joining trees in MEGA7 (26) by using a percentage distance method, a pairwise deletion option, and 1,000 bootstrap replicates. We analyzed either the junction of the envelope and the nonstructural protein 1 (NS1) encoding regions (polyprotein gene positions 2215–2454) or a fragment of 561 nt within the NS1 region (polyprotein gene positions 2650–3210). For clarity of presentation, we excluded sequences of <0.5% mutual nucleotide sequence distance. To show different genotypes, we included selected reference strains (Appendix Table 2). All DENV genome positions given within this article refer to a DENV prototype strain available in GenBank under accession no. KC294223.

Confirmation of DENV Strains Used for PRNT

We confirmed the designation and serotype of DENV strains applied for PRNT by Sanger sequencing of the prM-C domains and strain-specific oligonucleotide primers. These primers are available upon request.

Statistical Analyses and Visualization of PRNT Results

To plot PRNT results, we used GraphPad Prism 6. All p values result from 2-tailed tests. For power calculations, we used OpenEpi version 3 (27) for 2-sided 95% CIs. Regression lines were calculated by using a least squares (ordinary) fit method.

Model Testing

To compare the effects of different factors on CZS formation, we tested mathematical logistic regression models. Each model considered 1 defined variable to predict the binary outcome as CZS case or control. We included for testing binary predictor variables such as presence or absence of DENV-1 neutralization, as well as ordinal (e.g., number of neutralized DENV serotypes) or continuous predictor variables, such as DENV-1 PRNT titers. Cases were coded as 1 and controls as 0. We fitted 14 models by using the generalized linear model function of R version 3.5.2 ( To compare different models, we calculated the Akaike information criterion (AIC), the difference between a given and the best-supported model in AIC, and the Akaike weights by using the bbmle package version 1.0.20 in R. To show which models allow significant CZS case prediction, we calculated likelihood ratio tests for each model. To show the effect strength of the models, we calculated odds ratios.


Figure 1

Thumbnail of Timeline of dengue virus introduction in Brazil and birth years of participants in study of dengue virus cross-protection against congenital Zika syndrome, northeastern Brazil. DENV, dengue virus.

Figure 1. Timeline of dengue virus introduction in Brazil and birth years of participants in study of dengue virus cross-protection against congenital Zika syndrome, northeastern Brazil. DENV, dengue virus.

Figure 2

Thumbnail of Phylogenies of dengue virus strains from Brazil. Strains circulating in northeastern and remaining Brazil are grouped in intervals of 5 years. A) Envelope-NS1 junction phylogeny. Roman numerals indicate reference sequences for relevant DENV genotypes (Appendix Table 2). DENV-2 genotypes identified by Roman numerals represent the following geographic designations: I, Asian I; II, Asian II; III, American; IV, cosmopolitan I; V, cosmopolitan II; VI, cosmopolitan III; VII, Asian/America

Figure 2. Phylogenies of dengue virus strains from Brazil. Strains circulating in northeastern and remaining Brazil are grouped in intervals of 5 years. A) Envelope-NS1 junction phylogeny. Roman numerals indicate reference sequences for...

After the reinfestation of Brazil with the main DENV vector, Aedes aegypti mosquitoes, in 1976 (28), DENV-1 was introduced in 1986 (29), DENV-2 in 1990 (30), and DENV-3 in 2000 (31); DENV-4 reemerged in 2007 after 25 years of absence (32) (Figure 1). At most, 4 years after their first detection in other regions of Brazil, all 4 DENV serotypes were found in northeastern Brazil. In the databases, we identified 992 unique DENV sequences from Brazil that we used to analyze genomic DENV signatures hypothetically segregating the northeast and other regions in Brazil. Analyses of the envelope-NS1 junction, which is frequently used for genome-based serotyping (33), revealed high genetic identity of DENV strains from the northeast and other regions of Brazil during 30 years (Figure 2, panel A). A single DENV-4 clade apparently was found uniquely in northeastern Brazil during 2011–2015 (Figure 2, panel A). Nonetheless, these DENV-4 strains were closely related to strains from other regions when a different, larger, partial NS1 region was analyzed (Figure 2, panel B). In summary, our analyses showed no phylogenetic evidence for a unique DENV signature segregating northeastern Brazil from other regions.

Figure 3

Thumbnail of Serologic test results from participants in case–control study of cross-protection of dengue virus infection against congenital Zika syndrome, northeastern Brazil. A) Serotype-specific PRNT90 titers for cases and controls. Statistical significance (p&lt;0.05) were calculated by the Mann–Whitney U test; no significance was found. B) Zika virus neutralizing antibody titers as a function of the number of neutralized DENV serotypes. C) Correlation of DENV and Zika virus titers. Statisti

Figure 3. Serologic test results from participants in case–control study of cross-protection of dengue virus infection against congenital Zika syndrome, northeastern Brazil. A) Serotype-specific PRNT90 titers for cases and controls. Statistical significance (p<0.05)...

Low DENV antibody titers have been shown to be a risk factor for severe disease with heterotypic DENV infection (15). Therefore, we analyzed the magnitude of DENV antibody titers. Overall median reciprocal PRNT90 titers within this study were 56.5 (95% CI 42.0–79.0) for cases and 61.4 (95% CI 54.3–73.1) for controls. Serotype-specific titers were 68.7 (95% CI 51.2–83.2) for DENV-1, 102.8 (95% CI 79.6–130.6) for DENV-2, 44.8 (95% CI 35.3–55.8) for DENV-3, and 52.6 (95% CI 41.9–66.6) for DENV-4. DENV titers did not differ significantly between cases and controls or between serotypes (Figure 3, panel A). However, we have previously shown that Zika virus antibody titers are significantly higher among mothers of neonates with CZS than among mothers of neonates without evidence of CZS (34), hypothetically affecting DENV antibody titer estimates. In our cohorts, Zika virus titers did not correlate with DENV titers (Figure 3, panel B) or with the number of neutralized DENV serotypes (p = 0.8459 by analysis of variance) (Figure 3, panel C), suggesting robustness of our results irrespective of individual Zika virus PRNT titers.

Figure 4

Thumbnail of Dengue virus prevalence and neutralization among participants in case–control study of cross-protection of dengue virus infection against congenital Zika syndrome, northeastern Brazil. A) Serotype-specific DENV seroprevalence in cases and controls. Statistical significance was calculated by χ2 test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001. B) Multitypic DENV neutralization in cases and controls. Statistical significance for the numbers of neutralized DENV serotypes w

Figure 4. Dengue virus prevalence and neutralization among participants in case–control study of cross-protection of dengue virus infection against congenital Zika syndrome, northeastern Brazil. A) Serotype-specific DENV seroprevalence in cases and controls. Statistical...

Strikingly, the overall DENV seroprevalence was significantly lower among cases, at 65.5%, than among controls, at 91.7% (p = 0.0003 by χ2 test; power 90.4%). For each DENV serotype, seroprevalence was also consistently higher among cases than controls (Figure 4, panel A). The relatively lower seroprevalence of DENV-3 and DENV-4 compared with DENV-1 and DENV-2 among study participants is consistent with the shorter circulation of these viruses in Brazil (Figure 1), again suggesting robustness of our data. Last, the median number of neutralized DENV serotypes was significantly lower among cases than among controls (p<0.0004 by Mann-Whitney U test; power 94.8%) (Figure 4, panel B). Only 27.6% of cases, compared with 50.9% of controls, had neutralizing antibodies against all 4 serotypes. Predominance of multitypic DENV exposure among controls over cases was consistently observed among participants in all age groups (Figure 4, panel C).

We conducted generalized linear model analyses to compare the effects of various factors on CZS formation. For model analysis, we considered factors that differed significantly between cases and controls in bivariate comparisons and factors that did not differ significantly. Factors included the presence and titers of neutralizing antibodies against specific DENV serotypes and the overall number of neutralized serotypes. We created 14 logistic regression models, each considering 1 factor potentially affecting CZS development (Table). With our data applied, the models considering neutralization of >2 DENV serotypes (AIC = 130.4) or the cumulative number of neutralized DENV serotypes showed the highest support (AIC = 130.6). Regarding the presence of serotype-specific neutralizing antibodies, models considering DENV-4 (AIC = 131.4) and DENV-2 (AIC = 131.5) neutralization showed the best support. Models considering age or antibody titers showed relatively lower support with AICs >140. Of all tested models, the model considering neutralization of >2 DENV serotypes showed the highest reduction of CZS risk by 84.2% (95% CI 60.5%–93.8%). Of those models considering nonbinary factors, the cumulative number of neutralized DENV serotypes showed the highest reduction of CZS risk by 42.3% (95% CI 23.7%–56.8%) per increase of neutralized serotype.


Contrary to a large body of in vitro data, our epidemiologic data strongly suggest cross-protection from CZS development by multitypic DENV immunity. The protective effect was observed in bivariate comparisons and in model analyses. Our interpretation is consistent with anecdotal evidence reporting near-complete lack of DENV activity during the Zika virus epidemic, hypothetically resulting from cross-protection induced by previous Zika virus exposure (35). Moreover, in experimentally infected nonhuman primates, preexisting DENV immunity caused relatively faster clearance of Zika viremia (22). Strong support for our interpretation is provided by 2 recently published epidemiologic studies from Brazil and Nicaragua (36,37). In both studies, preexisting DENV immunity significantly reduced the risk for symptomatic Zika virus infection. Although those studies did not examine the effect of serotype-specific antibodies, in several epidemiologic studies, multitypic DENV immunity was cross-protective for postsecondary DENV infections (15,38,39). In our study, the relatively stronger cross-protection by neutralization of DENV-2 and DENV-4 may suggest that recent DENV infection boosts cross-protection against CZS because both serotypes reportedly were the predominant serotypes in northeastern Brazil before the Zika virus outbreak (40).

Antibody protection against DENV is related to antibody titers, and low titers are a risk factor for severe dengue (15). In our study, putative DENV-mediated cross-protection against CZS was apparently not linked to antibody titers. Thus, cross-protection from CZS may be mediated by immune responses (41) other than cross-protective antibodies. In humans, preexisting DENV immunity has been shown to boost CD4+ and CD8+ T-cell responses during Zika virus infections (4244). In pregnant mice, DENV cross-reactive CD8+ T cells have been shown to be a key component of protection from fetal injury or demise during Zika virus infection (45,46). Of note, CD8+ T cells form a part of the placental barrier that protects the fetus from vertically acquired infections. DENV-primed CD8+ T cells might provide cross-protection from CZS at the placental barrier (45). As T-cell–mediated DENV cross-protection wanes over time (39,45), consecutive heterotypic DENV infections might have afforded relatively stronger and prolonged cross-protection from CZS in controls.

Our study was limited by the absence of longitudinal samples, thereby preventing definite assessments of identical DENV serostatus at the time of congenital Zika virus infection compared with the time of testing at delivery. Nonetheless, the uniformity of our results and low DENV activity during the Zika epidemic (1,35) speak against putative DENV exposure of mothers after the time of congenital Zika virus infection. Because sampling was conducted at delivery, we could not assess the time of maternal and potential congenital Zika virus infection, which affects CZS development (2). Because the dates of deliveries were similar among cases and controls sampled continuously within Salvador during the peak of the Zika outbreak (1), it seems plausible that cases and controls acquired Zika virus infection at similar stages of pregnancy (i.e., cases were probably not exclusively infected during the first trimester of pregnancy, which is most critical for CZS formation, compared with putatively later times of maternal infection in controls). Because of the small sample sizes, we could not perform PRNT for other endemic flaviviruses (e.g., yellow fever virus) that may also affect CZS development (19). However, northeastern Brazil has not consistently implemented yellow fever vaccination, and samples were collected before the large yellow fever outbreak that struck Brazil in the aftermath of the Zika epidemic (47). The comparison of historic DENV circulation in northeastern Brazil and other regions of the country is limited by incomplete genome coverage, sampling biases, and resolution of the phylogenetic trees. Nevertheless, our results match the cornerstones of DENV circulation in Brazil and the dataset is larger than other virus databases. The strengths of our study include the combination of highly specific serotype-discriminating DENV PRNT90 for examination of preexisting DENV immunity with serologically well-characterized samples from the most relevant persons (i.e., cases and controls sampled during the same time and in the same region) (13,34), model selection analyses, and an analysis of historical DENV exposure in Brazil.

Our data do not exclude the possibility of sporadic enhancement of CZS development by monotypic DENV immunity or subneutralizing antibodies from nonrecent exposure to DENV depending on the combination (48) and the chronologic sequence (49) of previous flavivirus infection and the time since previous flavivirus infections (50). However, our study strongly suggests a complex interaction between Zika virus and DENV immunity and a protective effect of strong preexisting multitypic DENV immunity of the mother on CZS development in the fetus during the Zika virus outbreak in northeastern Brazil.

Dr. Pedroso is a researcher at the Universidade Federal de Bahia in Salvador. Her research focuses on the pathogenesis of infectious diseases.



We thank Petra Emmerich and Jonas Schmidt-Chanasit for providing dengue viruses and Janett Wieseler for technical support.

This work was supported by the German Centre for Infection Research through the ZIKApath project, an intramural funding program at the University of Bonn, and the European Union’s Horizon 2020 research and innovation program through the ZIKAlliance project (grant agreement no. 734548). The data used are part of the thesis of M.F.



  1. Netto  EM, Moreira-Soto  A, Pedroso  C, Höser  C, Funk  S, Kucharski  AJ, et al. High Zika virus seroprevalence in Salvador, northeastern Brazil limits the potential for further outbreaks. MBio. 2017;8:e0139017. DOIPubMed
  2. Brasil  P, Pereira  JP Jr, Moreira  ME, Ribeiro Nogueira  RM, Damasceno  L, Wakimoto  M, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375:232134. DOIPubMed
  3. França  GV, Schuler-Faccini  L, Oliveira  WK, Henriques  CM, Carmo  EH, Pedi  VD, et al. Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation. Lancet. 2016;388:8917. DOIPubMed
  4. de Oliveira  WK, de França  GVA, Carmo  EH, Duncan  BB, de Souza Kuchenbecker  R, Schmidt  MI. Infection-related microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. Lancet. 2017;390:86170. DOIPubMed
  5. de Araújo  TVB, Ximenes  RAA, Miranda-Filho  DB, Souza  WV, Montarroyos  UR, de Melo  APL, et al.; investigators from the Microcephaly Epidemic Research Group; Brazilian Ministry of Health; Pan American Health Organization; Instituto de Medicina Integral Professor Fernando Figueira; State Health Department of Pernambuco. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study. Lancet Infect Dis. 2018;18:32836. DOIPubMed
  6. Cugola  FR, Fernandes  IR, Russo  FB, Freitas  BC, Dias  JL, Guimarães  KP, et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature. 2016;534:26771. DOIPubMed
  7. Aiken  AR, Scott  JG, Gomperts  R, Trussell  J, Worrell  M, Aiken  CE. Requests for abortion in Latin America related to concern about Zika virus exposure. N Engl J Med. 2016;375:3968. DOIPubMed
  8. Mayor  S. Abortion requests increase in Latin America after Zika warning, figures show. BMJ. 2016;353:i3492. DOIPubMed
  9. Campos  MC, Dombrowski  JG, Phelan  J, Marinho  CRF, Hibberd  M, Clark  TG, et al. Zika might not be acting alone: Using an ecological study approach to investigate potential co-acting risk factors for an unusual pattern of microcephaly in Brazil. PLoS One. 2018;13:e0201452. DOIPubMed
  10. Faria  NR, Quick  J, Claro  IM, Thézé  J, de Jesus  JG, Giovanetti  M, et al. Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature. 2017;546:40610. DOIPubMed
  11. Pettersson  JH, Bohlin  J, Dupont-Rouzeyrol  M, Brynildsrud  OB, Alfsnes  K, Cao-Lormeau  VM, et al. Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia. Emerg Microbes Infect. 2018;7:79. DOIPubMed
  12. Butler  D. Brazil asks whether Zika acts alone to cause birth defects. Nature. 2016;535:4756. DOIPubMed
  13. Moreira-Soto  A, Cabral  R, Pedroso  C, Eschbach-Bludau  M, Rockstroh  A, Vargas  LA, et al. Exhaustive TORCH pathogen diagnostics corroborate Zika virus etiology of congenital malformations in northeastern Brazil. MSphere. 2018;3:e0027818. DOIPubMed
  14. Moureau  G, Cook  S, Lemey  P, Nougairede  A, Forrester  NL, Khasnatinov  M, et al. New insights into flavivirus evolution, taxonomy and biogeographic history, extended by analysis of canonical and alternative coding sequences. PLoS One. 2015;10:e0117849. DOIPubMed
  15. Katzelnick  LC, Gresh  L, Halloran  ME, Mercado  JC, Kuan  G, Gordon  A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:92932. DOIPubMed
  16. Halstead  SB, Mahalingam  S, Marovich  MA, Ubol  S, Mosser  DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10:71222. DOIPubMed
  17. Li  M, Zhao  L, Zhang  C, Wang  X, Hong  W, Sun  J, et al. Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors. PLoS One. 2018;13:e0200478. DOIPubMed
  18. Hermanns  K, Göhner  C, Kopp  A, Schmidt  A, Merz  WM, Markert  UR, et al. Zika virus infection in human placental tissue explants is enhanced in the presence of dengue virus antibodies in-vitro. Emerg Microbes Infect. 2018;7:198. DOIPubMed
  19. Bardina  SV, Bunduc  P, Tripathi  S, Duehr  J, Frere  JJ, Brown  JA, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356:17580. DOIPubMed
  20. Castanha  PMS, Nascimento  EJM, Braga  C, Cordeiro  MT, de Carvalho  OV, de Mendonça  LR, et al. Dengue virus-specific antibodies enhance Brazilian Zika virus infection. J Infect Dis. 2017;215:7815.PubMed
  21. Priyamvada  L, Hudson  W, Ahmed  R, Wrammert  J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect. 2017;6:e33. DOIPubMed
  22. Pantoja  P, Pérez-Guzmán  EX, Rodríguez  IV, White  LJ, González  O, Serrano  C, et al. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017;8:15674. DOIPubMed
  23. Terzian  ACB, Schanoski  AS, Mota  MTO, da Silva  RA, Estofolete  CF, Colombo  TE, et al. Viral load and cytokine response profile does not support antibody-dependent enhancement in dengue-primed Zika virus-infected patients. Clin Infect Dis. 2017;65:12605. DOIPubMed
  24. Moore  CA, Staples  JE, Dobyns  WB, Pessoa  A, Ventura  CV, Fonseca  EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr. 2017;171:28895. DOIPubMed
  25. Kirkpatrick  BD, Whitehead  SS, Pierce  KK, Tibery  CM, Grier  PL, Hynes  NA, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016;8:330ra36. DOIPubMed
  26. Kumar  S, Stecher  G, Tamura  K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:18704. DOIPubMed
  27. Sullivan  KM, Dean  A, Soe  MM. OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public Health Rep. 2009;124:4714. DOIPubMed
  28. Pan American Health Organization. The feasibility of eradicating Aedes aegypti in the Americas. Rev Panam Salud Publica. 1997;1:6872. DOIPubMed
  29. Schatzmayr  HG, Nogueira  RM, Travassos da Rosa  AP. An outbreak of dengue virus at Rio de Janeiro—1986. Mem Inst Oswaldo Cruz. 1986;81:2456. DOIPubMed
  30. Nogueira  RM, Miagostovich  MP, Lampe  E, Souza  RW, Zagne  SM, Schatzmayr  HG. Dengue epidemic in the stage of Rio de Janeiro, Brazil, 1990-1: co-circulation of dengue 1 and dengue 2 serotypes. Epidemiol Infect. 1993;111:16370. DOIPubMed
  31. Nogueira  RM, Miagostovich  MP, de Filippis  AM, Pereira  MA, Schatzmayr  HG. Dengue virus type 3 in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz. 2001;96:9256. DOIPubMed
  32. Figueiredo  RM, Naveca  FG, Bastos  MS, Melo  MN, Viana  SS, Mourão  MP, et al. Dengue virus type 4, Manaus, Brazil. Emerg Infect Dis. 2008;14:6679. DOIPubMed
  33. Kurolt  IC, Betica-Radić  L, Daković-Rode  O, Franco  L, Zelená  H, Tenorio  A, et al. Molecular characterization of dengue virus 1 from autochthonous dengue fever cases in Croatia. Clin Microbiol Infect. 2013;19:E1635. DOIPubMed
  34. Moreira-Soto  A, Sarno  M, Pedroso  C, Netto  EM, Rockstroh  A, Luz  E, et al. Evidence for congenital Zika virus infection from neutralizing antibody titers in maternal sera, northeastern Brazil. J Infect Dis. 2017;216:15014. DOIPubMed
  35. Ribeiro  GS, Kikuti  M, Tauro  LB, Nascimento  LCJ, Cardoso  CW, Campos  GS, et al.; Salvador Arboviral Research Group. Does immunity after Zika virus infection cross-protect against dengue? Lancet Glob Health. 2018;6:e1401. DOIPubMed
  36. Rodriguez-Barraquer  I, Costa  F, Nascimento  EJM, Nery  N, Castanha  PMS, Sacramento  GA, et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science. 2019;363:60710. DOIPubMed
  37. Gordon  A, Gresh  L, Ojeda  S, Katzelnick  LC, Sanchez  N, Mercado  JC, et al. Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua. PLoS Med. 2019;16:e1002726. DOIPubMed
  38. Olkowski  S, Forshey  BM, Morrison  AC, Rocha  C, Vilcarromero  S, Halsey  ES, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013;208:102633. DOIPubMed
  39. Uno  N, Ross  TM. Dengue virus and the host innate immune response. Emerg Microbes Infect. 2018;7:167. DOIPubMed
  40. Salles  TS, da Encarnação Sá-Guimarães  T, de Alvarenga  ESL, Guimarães-Ribeiro  V, de Meneses  MDF, de Castro-Salles  PF, et al. History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review. Parasit Vectors. 2018;11:264. DOIPubMed
  41. Collins  M, de Silva  A. Host response: Cross-fit T cells battle Zika virus. Nat Microbiol. 2017;2:17082. DOIPubMed
  42. Grifoni  A, Pham  J, Sidney  J, O’Rourke  PH, Paul  S, Peters  B, et al. Prior dengue virus exposure shapes T cell immunity to Zika virus in humans. J Virol. 2017;91:e0146917. DOIPubMed
  43. Delgado  FG, Torres  KI, Castellanos  JE, Romero-Sánchez  C, Simon-Lorière  E, Sakuntabhai  A, et al. Improved immune responses against Zika virus after sequential dengue and Zika virus infection in humans. Viruses. 2018;10:E480. DOIPubMed
  44. Saron  WAA, Rathore  APS, Ting  L, Ooi  EE, Low  J, Abraham  SN, et al. Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. Sci Adv. 2018;4:eaar4297. PMID: 29978039
  45. Regla-Nava  JA, Elong Ngono  A, Viramontes  KM, Huynh  AT, Wang  YT, Nguyen  AT, et al. Cross-reactive Dengue virus-specific CD8+ T cells protect against Zika virus during pregnancy. Nat Commun. 2018;9:3042. DOIPubMed
  46. Wen  J, Tang  WW, Sheets  N, Ellison  J, Sette  A, Kim  K, et al. Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells. Nat Microbiol. 2017;2:17036. DOIPubMed
  47. Moreira-Soto  A, Torres  MC, Lima de Mendonça  MC, Mares-Guia  MA, Dos Santos Rodrigues  CD, Fabri  AA, et al. Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil. Clin Microbiol Infect. 2018;24:1019.e14. DOIPubMed
  48. Guzman  MG, Alvarez  A, Vazquez  S, Alvarez  M, Rosario  D, Pelaez  O, et al. Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002. Int J Infect Dis. 2012;16:e198203. DOIPubMed
  49. Katzelnick  LC, Harris  E; Participants in the Summit on Dengue Immune Correlates of Protection. Immune correlates of protection for dengue: State of the art and research agenda. Vaccine. 2017;35:465969. DOIPubMed
  50. OhAinle  M, Balmaseda  A, Macalalad  AR, Tellez  Y, Zody  MC, Saborío  S, et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med. 2011;3:114ra128. DOIPubMed




Suggested citation for this article: Pedroso C, Fischer C, Feldmann M, Sarno M, Luz E, Moreira-Soto A, et al. Cross-protection of dengue virus infection against congenital Zika syndrome, northeastern Brazil. Emerg Infect Dis. 2019 Aug [date cited].

DOI: 10.3201/eid2508.190113

Original Publication Date: 5/10/2019

1These authors contributed equally to this article.

Table of Contents – Volume 25, Number 8—August 2019


Please use the form below to submit correspondence to the authors or contact them at the following address:

Jan Felix Drexler, Charité, Universitätsmedizin Berlin, Institute of Virology, Helmut-Ruska-Haus Charitéplatz 1, 10098 Berlin, Germany

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.


Page created: May 15, 2019
Page updated: May 15, 2019
Page reviewed: May 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.